




RealRate

PHARMACEUTICAL 2021

Sonoma Pharmaceuticals Inc.
Rank 131 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Sonoma Pharmaceuticals Inc. Rank 131 of 409



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 713% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 363% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 331% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	12,383
Cost of Goods Sold	10,603
Intangible Assets	0
Liabilities, Current	4,865
Liabilities, Non-Current	746
Other Assets	1,813
Other Compr. Net Income	0
Other Expenses	137
Other Liabilities	245
Other Net Income	3,862
Property and Equipment	365
Research and Development	1,339
Revenues	18,936
Selling, General and Administrative Expense	13,665

Output Variable	Value in 1000 USD
Assets	14,561
Liabilities	5,856
Expenses	25,744
Stockholders Equity	8,705
Net Income	-2,946
Comprehensive Net Income	-2,946
Economic Capital Ratio	-23%

